Le microenvironnement immunitaire, complice de la voie Wnt/β-caténine dans le cancer du foie

Marie Anson; Mireille Viguier; Christine Perret; Jean-Pierre Couty

doi:10.1051/medsci/2012285010

Accueil

Tous les numéros

Volume 28 / Numéro 5 (Mai 2012)

Med Sci (Paris), 28 5 (2012) 473-475

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 28, Numéro 5, Mai 2012


Page(s)		473 - 475
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/2012285010
Publié en ligne		30 mai 2012

El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 ; 132 : 2557–2576. [CrossRef] [PubMed] [Google Scholar]
Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006 ; 25 : 3778–3786. [CrossRef] [PubMed] [Google Scholar]
De La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998 ; 95 : 8847–8851. [CrossRef] [Google Scholar]
Clevers H. Colon cancer: understanding how NSAIDs work. N Engl J Med 2006 ; 354 : 761–763. [CrossRef] [PubMed] [Google Scholar]
Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004 ; 20 : 781–810. [CrossRef] [PubMed] [Google Scholar]
MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009 ; 17 : 9–26. [CrossRef] [PubMed] [Google Scholar]
Benhamouche S, Decaens T, Godard C, et al. Apc tumor suppressor gene is the zonation-keeper of mouse liver. Dev Cell 2006 ; 10 : 759–770. [CrossRef] [PubMed] [Google Scholar]
Colnot S, Decaens T, Niwa-Kawakita M, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA 2004 ; 101 : 17216–17221. [CrossRef] [Google Scholar]
Torre C, Benhamouche S, Mitchell C, et al. The transforming growth factor-alpha and cyclin D1 genes are direct targets of beta-catenin signaling in hepatocyte proliferation. J Hepatol 2011 ; 55 : 86–95. [CrossRef] [PubMed] [Google Scholar]
Ovejero C, Cavard C, Périanin A, et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 2004 ; 40 : 167–176. [CrossRef] [PubMed] [Google Scholar]
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 ; 144 : 646–674. [CrossRef] [PubMed] [Google Scholar]
Anson M, Crain-Denoyelle AM, Baud V, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 2012 ; 122 : 586–599. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007 ; 132 : 2557–2576. [CrossRef] [PubMed] [Google Scholar]

[2] Laurent-Puig P, Zucman-Rossi J. Genetics of hepatocellular tumors. Oncogene 2006 ; 25 : 3778–3786. [CrossRef] [PubMed] [Google Scholar]

[3] De La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998 ; 95 : 8847–8851. [CrossRef] [Google Scholar]

[4] Clevers H. Colon cancer: understanding how NSAIDs work. N Engl J Med 2006 ; 354 : 761–763. [CrossRef] [PubMed] [Google Scholar]

[5] Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004 ; 20 : 781–810. [CrossRef] [PubMed] [Google Scholar]

[6] MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009 ; 17 : 9–26. [CrossRef] [PubMed] [Google Scholar]

[7] Benhamouche S, Decaens T, Godard C, et al. Apc tumor suppressor gene is the zonation-keeper of mouse liver. Dev Cell 2006 ; 10 : 759–770. [CrossRef] [PubMed] [Google Scholar]

[8] Colnot S, Decaens T, Niwa-Kawakita M, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci USA 2004 ; 101 : 17216–17221. [CrossRef] [Google Scholar]

[9] Torre C, Benhamouche S, Mitchell C, et al. The transforming growth factor-alpha and cyclin D1 genes are direct targets of beta-catenin signaling in hepatocyte proliferation. J Hepatol 2011 ; 55 : 86–95. [CrossRef] [PubMed] [Google Scholar]

[10] Ovejero C, Cavard C, Périanin A, et al. Identification of the leukocyte cell-derived chemotaxin 2 as a direct target gene of beta-catenin in the liver. Hepatology 2004 ; 40 : 167–176. [CrossRef] [PubMed] [Google Scholar]

[11] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 ; 144 : 646–674. [CrossRef] [PubMed] [Google Scholar]

[12] Anson M, Crain-Denoyelle AM, Baud V, et al. Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 2012 ; 122 : 586–599. [CrossRef] [PubMed] [Google Scholar]